• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Third Harmonic Bio Inc.

    7/31/25 6:07:49 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THRD alert in real time by email
    POS AM 1 d71435dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on July 31, 2025

    Registration No. 333-    

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    Post-Effective Amendment No. 1

    to

    Form S-3

    Registration Statement No. 333-274823

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    THIRD HARMONIC BIO, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   83-4553503
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

    1700 Montgomery Street, Suite 210

    San Francisco, California 94111

    (209) 727-2457

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Natalie Holles

    Chief Executive Officer

    Third Harmonic Bio, Inc.

    1700 Montgomery Street, Suite 210

    San Francisco, California 94111

    (209) 727-2457

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Effie Toshav, Esq.

    Robert A. Freedman, Esq.

    Ryan Mitteness, Esq.

    Fenwick & West LLP

    401 Union Street, 5th Floor

    Seattle, WA 98101

    (206) 389-4510

     

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:☒

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earliest effective registration statement for the same offering: ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I. D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
    Emerging growth company   ☒     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment relates to the following Registration Statement on Form S-3 (the “Registration Statement”), previously filed by Third Harmonic Bio, Inc., a Delaware corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”):

     

      •  

    Registration Statement on Form S-3 (File No. 333-274823), originally filed with the SEC on October 2, 2023, registering such indeterminate number of shares of common stock and preferred stock, such indeterminate principal amount of debt securities and such indeterminate number of warrants to purchase common stock, preferred stock and/or debt securities, which together shall have an aggregate initial offering price not to exceed $400,000,000.

    On April 10, 2025, the Company’s board of directors approved a Plan of Dissolution (the “Plan of Dissolution”) which, following the approval by the Company’s stockholders at the annual meeting held on June 5, 2025, authorizes the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution. On July 31, 2025, the Company filed its Certificate of Dissolution with the Secretary of State of the State of Delaware, which became effective upon filing.

    In connection with the Plan of Dissolution, the Company is terminating any and all offerings of the Company’s securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statement. In accordance with undertakings made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, the Company hereby removes from registration all such securities of the Company registered pursuant to the Registration Statement that remain unsold as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on July 31, 2025.

     

    THIRD HARMONIC BIO, INC.
    By:   /s/ Christopher Murphy
      Christopher Murphy
      Chief Financial and Business Officer

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $THRD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THRD

    DatePrice TargetRatingAnalyst
    3/28/2025$23.00 → $5.00Buy → Hold
    Stifel
    2/12/2025$20.00 → $5.00Overweight → Equal-Weight
    Morgan Stanley
    2/11/2025Outperform → Mkt Perform
    Raymond James
    8/9/2024$12.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    6/18/2024$23.00Buy
    Stifel
    6/7/2024$18.00Outperform
    Raymond James
    More analyst ratings

    $THRD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

    Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected in the range between approximately $5.30 and $5.35 per share of common stock, expected in the third quarter of 2025 THB335 demonstrated 85% serum tryptase reduction with an encouraging safety profile in an additional Phase 1 cohort evaluating 100mg dose with new drug product capsule formulation Company initiating a sale process of THB335 SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD) today announced that its stockholders overwhelmingly approved the previously proposed Plan of Liquidation and

    6/12/25 8:00:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Third Harmonic Bio Announces Plan of Liquidation and Dissolution

    Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 Initial distribution expected in the range between approximately $246.6 million and $255.4 million, or approximately $5.13 and $5.33 per share of common stock, expected in the third quarter of 2025 Sale of the Company's assets, including THB335, to be initiated pending stockholder approval of the Plan of Liquidation and Dissolution SAN FRANCISCO, April 14, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD) today announced that the Company's board of directors, after considering opportunities to

    4/14/25 6:45:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

    Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across all assets in the company Strong financial position with cash and cash equivalents totaling $285.1 million as of December 31, 2024 SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024. THB335 Phase 1 Clinical Results In February 2025, the Company reported resu

    3/27/25 8:10:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    SEC Filings

    View All

    SEC Form 15-12G filed by Third Harmonic Bio Inc.

    15-12G - Third Harmonic Bio, Inc. (0001923840) (Filer)

    8/11/25 6:03:26 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Third Harmonic Bio Inc.

    EFFECT - Third Harmonic Bio, Inc. (0001923840) (Filer)

    8/1/25 12:15:04 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Third Harmonic Bio Inc.

    8-K - Third Harmonic Bio, Inc. (0001923840) (Filer)

    7/31/25 2:40:34 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Holles Natalie C. disposed of 1,218,836 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

    8/14/25 4:09:05 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Seidel Hans Martin disposed of 85,753 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

    8/14/25 4:06:24 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Soloway Thomas P

    4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

    8/14/25 4:05:41 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Third Harmonic Bio downgraded by Stifel with a new price target

    Stifel downgraded Third Harmonic Bio from Buy to Hold and set a new price target of $5.00 from $23.00 previously

    3/28/25 8:16:37 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Third Harmonic Bio downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Third Harmonic Bio from Overweight to Equal-Weight and set a new price target of $5.00 from $20.00 previously

    2/12/25 7:12:21 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Third Harmonic Bio downgraded by Raymond James

    Raymond James downgraded Third Harmonic Bio from Outperform to Mkt Perform

    2/11/25 11:05:35 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    Leadership Updates

    Live Leadership Updates

    View All

    Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

    SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. "Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, into clinical trials for chronic spontaneous urticaria," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "Beyond his expertise, Geoff is an excellent cultural fit with our organ

    3/28/24 8:30:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update

    Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion; Pre-IND interaction with the U.S. FDA now complete Program remains on track to file a U.S. IND and initiate a Phase 1 study of THB335 during the first half of 2024 SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Christopher Murphy as Chief Financial and Business Officer. Chris brings extensive experience in business de

    1/4/24 8:00:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    Financials

    Live finance-specific insights

    View All

    Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

    THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today

    2/11/25 7:00:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Third Harmonic Bio Inc.

    SC 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

    11/14/24 5:46:12 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Third Harmonic Bio Inc.

    SC 13G - Third Harmonic Bio, Inc. (0001923840) (Subject)

    11/14/24 1:28:35 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Third Harmonic Bio Inc.

    SC 13D/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

    11/12/24 6:04:36 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care